key: cord-0787623-5kwyacq6
authors: Danielle Dias Conte, D. D.; Carvalho, J. M. A.; de Souza Luna, L. K.; Faico-Filho, K. S.; Perosa, A. H.; Bellei, N. C. J.
title: Comparative analysis of point-of-care lateral flow immunoassays for the detection of IgM and IgG anti-SARS-CoV-2 antibodies in healthcare workers
date: 2020-11-12
journal: nan
DOI: 10.1101/2020.11.11.20229914
sha: 98bc323b927528d8c94e7e907985d83c363eca1b
doc_id: 787623
cord_uid: 5kwyacq6

Since the Coronavirus Disease 2019 (COVID-19) pandemic, Brazil has the third-highest number of confirmed cases and the second-highest number of recovered patients. SARS-CoV-2 detection by real-time RT-PCR is the gold standard in certified infrastructured laboratories. However, for large-scale testing, diagnostics should be fast, cost-effective, widely available, and deployed for the community, such as serological tests based on lateral flow immunoassay (LFIA) for IgM/IgG detection. We evaluated three different commercial point-of-care (POC) LFIAs for anti-SARS-CoV-2 IgM and IgG detection in capillary whole blood of 100 healthcare workers (HCW) previously tested by RT-PCR: 1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody Test (Wondfo, China). A total of 84 positives and 16 negatives HCW were tested. The data was also analyzed by the number of days after symptoms (DAS) in three groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). Overall detection was 85.71%, 47.62%, and 44.05% for Bioclin, Livzon, and Wondfo, respectively, with a specificity of 100%, and 98.75% for Livzon on storage serum samples. Bioclin was more sensitive (p<0.01), regardless of the DAS. Thus, the Bioclin can be used as a POC test to monitor SARS-CoV-2 seroconversion in HCW.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 12, 2020. ; https://doi.org/10.1101/2020.11.11.20229914 doi: medRxiv preprint Three commercial POC LFIAs for detection of anti-SARS-CoV-2 IgG and IgM were tested: 1) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 12, 2020. ; https://doi.org/10.1101/2020.11.11.20229914 doi: medRxiv preprint 

Bioclin LFIA demonstrated high sensitivity and specificity for IgG detection (85.71%), and a

185 Performance of a qualitative rapid chromatographic immunoassay to diagnose COVID-19 in patients 186 in a middle-income country

An interactive web-based dashboard to track COVID-19 in real time

Antibody responses to SARS-CoV-2 in patients with COVID-19

Profile of IgG and IgM antibodies 196 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Sensitivity of the Wondfo One Step COVID-19 198 test using serum samples

Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil

R: A Language and Environment for Statistical Computing, R Foundation for Statistical 205 Computing

Detection of 208 SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized 209 patients

Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends

Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing 214 dynamics of antibody responses to SARS-CoV-2

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019